---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（2018102321384012.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------
部分PAM处方信息仅供参考

通用名称：PAM (パム静注)

常用名：碘化磷定，唾液酸甲酯碘化物

欧洲通用名：Pralidoxime Iodide

配方名称：碘化磷定，注射液

药物分类名称：有机磷中毒解毒剂

药物分类号：3929

ATC代码：V03AB04

适应症，疗效和剂量方案

疗效

有机磷中毒

剂量方案

作为碘化磷定，通常静脉内注射1g成人。顺便提一下，应根据您的年龄和症状增加或减少。

使用说明

谨慎管理

重症肌无力[它可能表现出与正常人不同的反应，所以要注意肌肉症状。 ]

肾功能受损的患者[由于该药主要通过肾脏排泄，因此应谨慎使用。 ]

重要的基本关注

由于接受该药物的患者可能显示出比实际血糖水平更高的值，因此预先从制造商和销售者获得关于对血糖测量试剂和测量仪器的血糖测量值的影响的信息。 [接受该药物的患者可能显示高于实际血糖水平，并且通过基于假的高值施用诸如胰岛素的降糖药物，可能发生诸如昏迷的严重低血糖症状存在出现的危险。参见“对临床试验结果的影响”部分]

相互作用

联合注意

阿托品混合注射可能会延迟药物疗效的开始，所以如果你需要一起使用，不要与它混合。机制尚不清楚。

副作用

副作用发展概要

在136个调查案例中，8个（5.9％）观察到副作用。 （重估材料）

主要副作用为4例恶心（2.9％），1例胸部（0.7％），1例轻度不适（0.7％）等。

以下副作用包括不良反应报告等，其频率无法计算。

其他副作用

小于0.1至5％，频率未知

消化器官恶心口腔苦味感

循环器官胸部折磨，心律失常

其他轻度不适：下颌疲劳感，过度碘化症症状（鼻咽灼热感，腮腺痛）

对孕妇，孕妇，哺乳期妇女等进行管理。

对于怀孕妇女或可能怀孕的妇女，只有在判断治疗效益超出风险的情况下才能给予怀孕。 [可以接受的是，当向兔子中大量施用类似化合物（对磷脂肟-2-甲磺酸盐）时，它们被转移到胎儿中。 ]

对临床试验结果的影响

小心，因为它可能会影响血糖读数。据报道，该药物的紫外吸收光谱随pH的变化而变化，或该药物中含有的碘离子影响测定电极。 [见“重要的基本关注”部分]

应用说明

安培切割

因为这种药物使用单点切割安瓿，在安瓿切割时，用乙醇棉等擦拭颈部后，轻轻地在相反侧（向下方向），并且安瓿头的标记向上，以施加力切割。

药物药理学

胆碱酯酶（ChE）激活活性

在给小鼠施用对硫磷和其他七种有机磷酸盐试剂的实验中，允许恢复每个器官的ChE活性。 [1]

认识到在给小鼠施用对硫磷和其他八种有机磷酸盐试剂的实验中LD 50值增加。 [2]

在兔子接受对硫磷和其他8种有机磷酸盐试剂的实验中，允许恢复血液中的ChE活性。 [2]

使用人血的体外实验，已被接受恢复由Sumithion等人抑制的ChE活性。 9种有机磷酸盐。 [3]

有效成分的物理化学知识

俗名：Pralidoxime iodide

俗名：甲基碘化物pralidoxime

通用名（欧洲名称）：Pralidoxime Iodide

<化学名称：2-甲酰基-1-甲基吡啶鎓碘肟

分子式：C 7 H 9 IN 2 O p

分子量：264.06

熔点：约216℃（分解）

性质：黄色结晶或结晶性粉末，无气味，微苦。

微溶于水，微溶于甲醇，几乎不溶于乙醚或氯仿。

包装

Pam静脉注射500 mg

5安瓿

Generic name: Pam

common name: Pralidoxime iodide, pralidoxime methyl iodide

European general name: Pralidoxime Iodide

Formulation name: Pralidoxime iodide injection

Name of drug classification: Organophosphorus agent poisoning antidote

Drug classification number: 3929

ATC code: V03AB04

Indications, efficacy and dosage regimen

Efficacy effect

Organophosphorus poisoning

Dosage regimen

As a pralidoxime iodide, 1 g of adult is usually injected gradually intravenously. Incidentally, it should be increased or decreased according to your age and symptoms.

Usage notes

Careful Administration

Myasthenia gravis [It may show a different response from normal person, so be careful about muscle symptoms. ]

Patients with impaired renal function [As this drug is mainly excreted in the kidneys, it should be administered with caution. ]

Important basic attention

Since the patient who is receiving this drug may show a higher value than the actual blood glucose level, obtain information from the manufacturer and seller in advance about the influence on the blood glucose measurement value of the blood glucose measurement reagent and measuring instrument. [Patients who are receiving this drug may show higher than the actual blood glucose level, and by administering a hypoglycemic agent such as insulin based on the fake high value, severe hypoglycemic symptoms such as coma may occur There is a danger of appearing. See "Effect on clinical test results" section]

Interaction

Combined attention

Atropine Mixed injection may delay the onset of drug efficacy, so if you need to use it together, do not mix with it.The mechanism is unknown.

Side effect

Outline of side effect development

Side effects were observed in 8 (5.9%) of 136 survey cases. (Revaluation material)

The main side effects were 4 nausea (2.9%), 1 case in the chest (0.7%), 1 case of mild discomfort (0.7%), etc.

The following side effects include adverse reaction reports etc. whose frequency cannot be calculated.

Other side effects

Less than 0.1 to 5%, Frequency unknown

Digestive organ Nausea Oral bitterness sensation

Circulatory organ Chest torture, arrhythmia

Other Mild discomforts: Mandibular fatigue feeling,

excessive iodide symptoms (nasopharyngeal burning sensation, parotid pain)

Administration to pregnant women, maternity women, nursing women, etc.

For pregnant women or women who may be pregnant, only administer it if it is judged that the therapeutic benefit is beyond the risk. [It is accepted that when analogous compounds (pralidoxime-2-methanesulfonate) are administered to rabbits in large amounts, they are transferred to fetuses. ]

Impact on clinical test results

Be careful as it may affect blood glucose readings. It is reported that the ultraviolet absorption spectrum of this drug varies with pH or iodine ion contained in this drug affects the measuring electrode. [See "Important basic attention" section]

Application note

Ampere cut

Because this drug uses a one-point cut ampoule, at ampule cutting, after wiping around the neck with ethanol cotton etc., lightly in the opposite side (downward direction) with the ● mark of the ampoule head upward To cut by applying force.

Medicinal pharmacology

Cholinesterase (ChE) activation activity

It is permitted to restore the ChE activity of each organ in an experiment in which mice are administered parathion and seven other organophosphate agents. [1]

It is recognized that the LD50 value increases in experiments in which mice are administered parathion and eight other organophosphate agents. [2]

It is permitted to restore ChE activity in blood in experiments in which rabbits received parathion and eight other organophosphate agents. [2]

In vitro experiments using human blood, it has been accepted to restore ChE activity inhibited by Sumithion et al. 9 organophosphates. [3]

Physicochemical knowledge on active ingredients

common name: Pralidoxime iodide

common name: Methyl methyl iodide pralidoxime

Common name (European name): Pralidoxime Iodide

Chemical name: 2-formyl-1-methylpyridinium iodideoxime

Molecular formula: C 7 H 9 IN 2 O

Molecular weight: 264.06

Melting point: About 216 ° C (decomposition)

Property: It is a yellow crystal or a crystalline powder, it has no odor and taste slightly bitter.

It is slightly soluble in water, slightly soluble in methanol, and hardly soluble in ether or chloroform.

Packaging

Pam intravenous injection 500 mg

5 Ampoules

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（2018102321384012.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------